Date:  Sunday, June 3rd
Venue:  Joseph B. Martin Conference Center (Harvard Medical School)

In the advent of the International BIO Convention in Boston, join us for a day of healthcare and biomedical innovations at Taiwan Bio Forum, jointly hosted by MJNE and DCB on June 3rd at the Joseph B. Martin Conference Center at Harvard Medical School. Meet and network with top leaders in biopharma, medtech, venture capital, and academia from Taiwan and around the world.

This event will feature more than 20 speakers from Sanofi Genzyme, Samsung Ventures, LEO Pharma, SR One, M Ventures, MPM Capital, F-Prime Capital, Artiman Ventures, MIT Alumni Angels, Militia Hill Ventures, and Johnson & Johnson Innovation. The audience will also hear from keynote speakers Michael LaRhette, President, MassChallenge and Kate Merton, Head of JLABS at NYC & Boston, Johnson & Johnson Innovation.

Click photos for Speaker’s Bio

	Herbert Wu President DCB		Fong-Chin Su Deputy Minister Ministry of Science and Technology
	Michael LaRhette President MassChallenge		Chen-Yang Shen Chief Executive Taiwan Biobank
	David Lucchino Chairman MassBio		Johnsee Lee Chairman Taiwan Biotech Industry Organization
	Shaoyu Chang Investment Manager VI Ventures		Kate Merton Head of JLABS Johnson & Johnson Innovation
	Fulung Ko Chief Administrative Officer Taipei Exchange		Joan Lau Managing Partner Militia Hill Ventures
	Akhil Saklecha General Partner Artiman Ventures		Greg Sieczkiewicz Chief IP Counsel MPM Capital
	Kevin Chu Analyst F-Prime Capital		Christopher Kim Managing Partner Novatio Ventures
	Patrick DeCourcy Principal Program Manager Sanofi Genzyme		Vikas Goyal Associate SR One
	Hyuk-Jeen Suh Head of Investment Samsung Ventures		Michael Sierra Vice President LEO Sci. & Tech
	Daniel Franke Analyst M Ventures		Jeng-Shin Lee Chief Scientific Officer AB Biosciences
	Mary Ann Picard Dir. of Operation M2D2		Patrick Rivelli President Savran Technologies
	Ying K. Tam Managing Dir. of Health MaRS Ventures		Joel Berniac CEO and Co-Founder Akrivis Technologies

Technology Showcase:

Company Name	Brief Company Introduction	Speaker
ACT Genomics	​ACT Genomics is a leading CAP-accredited cancer molecular information service provider, with proprietary NGS-panels and chip-based platform, coupling with integrated medical informatics pipeline, we transform cancer treatment paradigm and support biopharma in biomarker exploration and companion diagnostic development.	Tsung-Kai Wu Sr. Associate Director, Business Development
Mao Ying Genetech Inc. ​	Mao Ying Genetech Inc. is a bioinformatics data analytic company dedicated to providing algorithmic technologies for diagnosis and therapy of cancer.  At Mao Ying, a multi-disciplinary team – comprising medical and computer scientists as well as a marketing expert – works together to develop diagnostic biomarkers for various types of cancer.  By applying the novel Gene Expression Portrait, we have successfully identified gene markers with potential applications to diagnosis or therapy, and developed several clinically validated products in this line, including OncoDx and MetaDx for cancer diagnosis and OrganID for human organ identification.	Pei-Ing Hwang​ General Manager
ASUS Life Corporation	ASUS Life focus on the development of smart medical application. With HealthCloud and AI application as the infrastructure, ASUS Life has PhenoFinder as a distributed database for medical data, OmniCare as a medical IoT platform, and AiNurse as a virtual application in telecare, to help hospitals develop the precision medicine.	Jerry Hsu Senior Manager
Augmented Intelligence, Inc.	Our mission is to create patient’s virtual avatar for better visualization to serve clinical and educational needs. Through Virtual Reality, our applications allow doctors to see through patient’s body for better surgical planning or radiotherapy simulation. In the student or patient education, the interactive and immersive learning experience enables users to eliminate conceptual hurdle so they can better understand human body. In Augmented Intelligence, our goal is to advance medical intelligence through simulated visualization.	Sam Jang CEO
Funique VR	​Funique dedicated into realizing Stereoscopic 3D VR in film industry, and creating new generation platform for viewers. Our Medical Stereo VR System - Observing Surgeries through Stereo VR Documenting all kinds of surgeries with Funique’s 8K per eye VR solution. Combining simulation and real-time footages, it solve the problems of lack of resources. And let medical students around the world have the chance to observe some of the greatest surgeons on earth.	Chien-Hsiang Chao Project Manager
Bio Preventive Medicine Corp.	Bio Preventive Medicine Corporation (BPM) is a clinical-staged biotech company, focusing on developing novel biomarker-based diagnostics for chronic diseases and oncology. Our first product, DNlite, is a non-invasive urinary test for predicting/monitoring the progression of Diabetic Kidney Disease (DKD), which has been applied to evaluate renal effect in a phase IIIb global clinical trial, MARLINA-T2D™, sponsored by Boehringer Ingelheim. We can help in the development of drugs not only in evaluating renal efficacy but also renal safety. BPM welcomes strategic partnerships in expanding the product pipeline and technology platform for biomarker detection, as well as international partnership for commercialization.	Dave Lee Scientist
LumiSTAR Biotechnology, Inc.	LumiSTAR Biotechnology is an expert in iPSC technology, optogenetic tools and functional indicators. There are two main applications of our technique: (1) All-optical platform incorporated with AI and machine learning for phenotypic screening, drug discovery, and toxicity testing. (2) Organs-on-chips for precision/personalized medicine.	Yu-Fen Chang, Ph.D President
GenomeFrontier Therapeutics, Inc.	​​CAR-T cell therapy is a gene therapy in which patients’ white blood cells are genetically engineered to fight their own cancer.  Achieving more than 90% remission rate in patients with advanced blood cancers, this innovative immunotherapy offers new hope to dying children and adults with advanced blood cancers.  Though powerful in treating advanced blood cancers, conventional CAR-T is futile in fighting solid tumors due to the drawbacks and limitation imposed by the viral vectors used in CAR-T cell engineering.  GenomeFrontier is poised to change the outlook for patients with otherwise incurable advanced solid cancers by confronting this very challenge with bold solutions using our core technologies including Quantum pBAc, a revolutionized non-viral genetic system capable of loading 30 times more genes than the viral method and an innovative cell culture system designed for expending engineered CAR-T cells to a therapeutic quantity while maintaining its potency.  With these revolutionary technologies, we are developing universal super CAR-T therapies for solid cancers which are virus-free, reversible, and potent enough for treating a wide-range of cancers in a much safer fashion than the conventional CAR-T therapies.	​Chiung-Yuan Wu CEO
Elixiron Immunotherapeutics Inc.	Elixiron Immunotherapeutics Inc. is a pre-clinical stage company focused on the development of transforming immunotherapy to treat chronic hepatitis B and cancer.  Our lead product EI001 is a fully human monoclonal antibody ready for IND-enabling studies as a potentially first-in-class curative HBV immunotherapy.  For cancer immunotherapy, we are developing therapeutic antibodies targeting tumor microenvironment to reactivate anti-tumor immunity and block cancer metastasis. Elixiron is positioned to launch our first clinical trial and deliver one additional drug candidate for clinical development in 18 months.	Hung-Kai Chen, M.D., Ph.D. CEO

Meeting Agenda:

More information:

Directions to the venue

Parking information